Foghorn Therapeutics Inc (FHTX)
Foghorn Therapeutics to Participate in Three Upcoming Investor Conferences
Altimmune Inc (ALT)
Altimmune Announces Early Completion of Enrollment in RECLAIM Phase 2 Trial Evaluating Pemvidutide in Alcohol Use Disorder
BridgeBio Pharma (BBIO)
BridgeBio to Present Data from the Overall ATTR-CM Variant and V142I (V122I) Populations from ATTRibute-CM at the AHA Scientific Sessions 2025
Biogen Inc (BIIB)
Biogen to Highlight Scientific Progress in Rare Kidney Disease at American Society of Nephrology (ASN) Kidney Week 2025
Dyne Therapeutics Inc (DYN)
Dyne Therapeutics to Present at Upcoming Investor Conferences
Clearbridge Health Limited (1H3)
Press Release Launch of Adult Immune Cell Banking Business
Clearbridge Health Limited (1H3)
General Announcement::Clearbridge Health Commencement of Adult Immune Cell Banking Business
ADC Therapeutics SA (ADCT)
ADC Therapeutics to Host Third Quarter 2025 Financial Results Conference Call on November 10, 2025
Benitec Biopharma Inc. (BNTC)
Benitec Biopharma Provides Positive Interim Clinical Study Results for BB-301 Phase 1b/2a Clinical Trial and Receives FDA Fast Track Designation for BB-301
Unicycive Therapeutics Inc. (UNCY)
Unicycive Therapeutics to Participate in a Fireside Chat at the Guggenheim 2nd Annual Healthcare Innovation Conference